Drugs / COVID-19 convalescent hyperimmune plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04392414 | May → Jul 2020 | COVID-19 | Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 convalescent hyperimmune plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04392414 ↗ |